Patrick Harriott

3.3k total citations
73 papers, 2.8k citations indexed

About

Patrick Harriott is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Patrick Harriott has authored 73 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Endocrinology, Diabetes and Metabolism, 29 papers in Oncology and 28 papers in Cellular and Molecular Neuroscience. Recurrent topics in Patrick Harriott's work include Diabetes Treatment and Management (39 papers), Peptidase Inhibition and Analysis (28 papers) and Neuropeptides and Animal Physiology (26 papers). Patrick Harriott is often cited by papers focused on Diabetes Treatment and Management (39 papers), Peptidase Inhibition and Analysis (28 papers) and Neuropeptides and Animal Physiology (26 papers). Patrick Harriott collaborates with scholars based in United Kingdom, Ireland and Australia. Patrick Harriott's co-authors include Victor A. Gault, Peter R. Flatt, Finbarr O’Harte, Brett Greer, Nigel Irwin, Clifford J. Bailey, Brian D. Green, Christian Hölscher, Paula L. McClean and Brian Walker and has published in prestigious journals such as Journal of Biological Chemistry, Blood and PLoS ONE.

In The Last Decade

Patrick Harriott

73 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patrick Harriott United Kingdom	34	1.4k	958	825	773	507	73	2.8k
Tatsuo Tomita United States	25	569 0.4×	755 0.8×	617 0.7×	809 1.0×	759 1.5×	119	3.3k
Timothy L. Reudelhuber Canada	38	1.1k 0.8×	1.7k 1.8×	245 0.3×	376 0.5×	631 1.2×	81	3.8k
Leena Haataja United States	38	897 0.7×	2.1k 2.1×	105 0.1×	2.6k 3.3×	939 1.9×	86	5.0k
Anthony J. Milici United States	32	198 0.1×	1.3k 1.3×	220 0.3×	524 0.7×	759 1.5×	53	2.9k
Susan B. Masters United States	20	519 0.4×	2.2k 2.3×	630 0.8×	267 0.3×	164 0.3×	28	3.2k
Priscilla S. Dannies United States	29	979 0.7×	1.2k 1.3×	410 0.5×	278 0.4×	266 0.5×	70	2.5k
Jun Takasaki Japan	25	334 0.2×	1.6k 1.6×	580 0.7×	366 0.5×	515 1.0×	43	2.8k
Stefano Thellung Italy	33	320 0.2×	1.5k 1.5×	307 0.4×	157 0.2×	455 0.9×	83	2.8k
Ken I. Mitchelhill Australia	20	466 0.3×	2.6k 2.7×	170 0.2×	1.0k 1.3×	1.0k 2.1×	25	3.5k
Thierry Grand‐Perret France	14	178 0.1×	2.2k 2.3×	455 0.6×	307 0.4×	372 0.7×	20	3.5k

Countries citing papers authored by Patrick Harriott

Since Specialization

Citations

This map shows the geographic impact of Patrick Harriott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Harriott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Harriott more than expected).

Fields of papers citing papers by Patrick Harriott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Harriott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Harriott. The network helps show where Patrick Harriott may publish in the future.

Co-authorship network of co-authors of Patrick Harriott

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Harriott. A scholar is included among the top collaborators of Patrick Harriott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Harriott. Patrick Harriott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ansari, Prawej, Peter R. Flatt, Patrick Harriott, & Yasser H.A. Abdel‐Wahab. (2021). Insulinotropic and antidiabetic properties of Eucalyptus citriodora leaves and isolation of bioactive phytomolecules. Journal of Pharmacy and Pharmacology. 73(8). 1049–1061. 19 indexed citations

Ansari, Prawej, Peter R. Flatt, Patrick Harriott, & Yasser H.A. Abdel‐Wahab. (2020). Anti-hyperglycaemic and insulin-releasing effects of Camellia sinensis leaves and isolation and characterisation of active compounds. British Journal Of Nutrition. 126(8). 1149–1163. 20 indexed citations

McClean, Paula L., Victor A. Gault, Patrick Harriott, & Christian Hölscher. (2009). Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease. European Journal of Pharmacology. 630(1-3). 158–162. 161 indexed citations

O’Harte, Finbarr, Kerry Hunter, Victor A. Gault, et al.. (2007). Antagonistic effects of two novel GIP analogs, (Hyp³)GIP and (Hyp³)GIPLys¹⁶PAL, on the biological actions of GIP and longer-term effects in diabeticob/obmice. American Journal of Physiology-Endocrinology and Metabolism. 292(6). E1674–E1682. 10 indexed citations

Hölscher, Christian, Simon Gengler, Victor A. Gault, Patrick Harriott, & Hanspeter A. Mallot. (2007). Soluble beta-amyloid[25–35] reversibly impairs hippocampal synaptic plasticity and spatial learning. European Journal of Pharmacology. 561(1-3). 85–90. 65 indexed citations

Irwin, Nigel, Paula L. McClean, Finbarr O’Harte, et al.. (2007). Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. Diabetologia. 50(7). 1532–1540. 88 indexed citations

Gault, Victor A., Kerry Hunter, Nigel Irwin, et al.. (2007). Characterisation and glucoregulatory actions of a novel acylated form of the (Pro3)GIP receptor antagonist in type 2 diabetes. Biological Chemistry. 388(2). 173–9. 14 indexed citations

Irwin, Nigel, Brian D. Green, Brett Greer, et al.. (2006). Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide. Biochemical Pharmacology. 72(6). 719–728. 34 indexed citations

Green, BD, Victor A. Gault, MH Mooney, et al.. (2004). Molecular, cellular and biological characteristics of DPP IV-resistant acetylated analogues of GLP-1.. Diabetic Medicine. 21. 26–26. 1 indexed citations

10.

Green, BD, MH Mooney, Victor A. Gault, et al.. (2004). N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity. Journal of Endocrinology. 180(3). 379–388. 50 indexed citations

11.

Green, BD, MH Mooney, Victor A. Gault, et al.. (2004). Lys9 for Glu9 substitution in glucagon-like peptide-1(7–36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9–36)amide and exendin (9–39). Metabolism. 53(2). 252–259. 32 indexed citations

12.

Green, BD, Victor A. Gault, Nigel Irwin, et al.. (2003). Metabolic Stability, Receptor Binding, cAMP Generation, Insulin Secretion and Antihyperglycaemic Activity of Novel N-Terminal Glu9-Substituted Analogues of Glucagon-Like Peptide-1. Biological Chemistry. 384(12). 1543–51. 23 indexed citations

13.

Green, BD, Victor A. Gault, MH Mooney, et al.. (2003). Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo. Journal of Molecular Endocrinology. 31(3). 529–540. 34 indexed citations

14.

Stitt, Alan W., et al.. (2002). Synthetic Peptides Interacting with the 67-kd Laminin Receptor Can Reduce Retinal Ischemia and Inhibit Hypoxia-Induced Retinal Neovascularization. American Journal Of Pathology. 160(1). 307–313. 36 indexed citations

15.

Greer, Brett, et al.. (2002). Kinetic Analysis of the Cleavage of Human Protease-Activated Receptor-1 / 2 / 3 and 4 Using Quenched-Fluorescent Peptide Substrates. Protein and Peptide Letters. 9(5). 387–393. 2 indexed citations

16.

Flatt, Peter R., Victor A. Gault, Patrick Harriott, & Finbarr O’Harte. (2001). Antagonist actions of novel (Pro(3))GIP analogue and GIP(3-42) on cyclic AMP production and insulin secretion. Diabetologia. 44. 1 indexed citations

17.

O’Harte, Finbarr, et al.. (2001). DPP IV resistant N-terminally modified GIP analogues with enhanced insulinotropic activity. Diabetologia. 44. 2 indexed citations

18.

McFerran, Neil V., et al.. (2000). Development of laminin receptor agonists: identification of important functional residues by alanine scanning. Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology. 1481(1). 25–36. 13 indexed citations

19.

Kapas, S., A. T. Cruchley, M. G. Macey, et al.. (1998). Immunolocalization of protease‐activated receptor‐2 in skin: receptor activation stimulates interleukin‐8 secretion by keratinocytes in vitro. Immunology. 94(3). 356–362. 111 indexed citations

20.

Macey, M. G., et al.. (1998). Protease‐activated receptors and their role in IL‐6 and NF‐IL‐6 expression in human gingival fibroblasts. Journal of Periodontal Research. 33(4). 205–211. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact